Evidence map›Paper›PMID 29417936›Full record

ReviewNature reviews. Disease primers2018

Rheumatoid arthritis.

Josef S Smolen, Daniel Aletaha, Anne Barton, Gerd R Burmester, Paul Emery, Gary S Firestein, Arthur Kavanaugh, Iain B McInnes, Daniel H Solomon, Vibeke Strand and 1 more

5 registry-linked trialsOpen access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Disease primers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04056039. Cited by 1,340 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,340citing papers in PubMed, 6 pooled it
142.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04056039 phase2completed

Efficacy of Atorvastatin vs Colchicine in Decrease of Troponin I of High Sensitivity as a Biomarker of Myocardial Damage in Patients With Rheumatoid Arthritis With Severe Activity.

Ran2018Enrolled60Registered outcomes3Posted comparisons0ConditionsArthritis, Rheumatoid, Cardiovascular DiseasesArmsAtorvastatin, Colchicine
PMID 24820145PMID 25533796PMID 25662717PMID 27580061PMID 27965879PMID 28610589PMID 29322198PMID 29331272PMID 29352092PMID 29353098PMID 29554376PMID 18926169other papers from this trial
Open the trial in the graph
NCT04092244 unknown statusnot on this mapstarted 2020, after this paper: background citation

CTHRC1 as a New Biomarker in Diagnosis of Rheumatoid Arthritis and Its Role in Seronegative Patients.

TypeobservationalSponsorAssiut UniversityRan2020 to 2021Enrolled90ConditionsRheumatoid ArthritisArmsCTHRC1 biomarker
NCT05480878 phase3completednot on this mapstarted 2022, after this paper: background citation

Clinical Study Evaluating the Efficacy of Nitazoxanide and Escitalopram as Adjuvant Therapies in Patients With Rheumatoid Arthritis

TypeinterventionalSponsorTanta UniversityRan2022 to 2023Enrolled90ConditionsRheumatoid ArthritisArmsPlacebo, Nitazoxanide 500Mg Oral Tablet, Escitalopram 10mg
NCT07105566 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Serum Triosephosphate Isomerase Level in Pateints With Rheumatoid Arthritis : Relation to Disease Activity and Structural Damage

TypeobservationalSponsorAssiut UniversityRan2025 to 2027Enrolled70ConditionsRheumatoid ArthritisArmsserum TPI
NCT07245732 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

STeroid Options for RA Management (STORM-RA): Oral Versus Intramuscular Steroid Use to Control Rheumatoid Arthritis Flares: A Pragmatic Randomized Clinical Trial

TypeinterventionalSponsorSunnybrook Health Sciences CentreRan2026 to 2029Enrolled220ConditionsRheumatoid Arthritis (RA)ArmsGlucocorticoid (GC)
3 · Its place in the literature

Who cites it

1,340 citing papers in PubMed, 6 syntheses or guidelines pooled it, 2,374 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1,280 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 5 countries.

Josef S SmolenDivision of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Daniel AletahaDivision of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Anne BartonArthritis Research UK Centre for Genetics and Genomics and NIHR Manchester Biomedical Research Centre, Manchester Academic Health Sciences Centre, The University of Manchester and Central Manchester Foundation Trust, Manchester, UK.
Gerd R BurmesterDepartment of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Paul EmeryLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK.
Gary S FiresteinDivision of Rheumatology, Allergy and Immunology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Arthur KavanaughDivision of Rheumatology, Allergy and Immunology, University of California-San Diego School of Medicine, La Jolla, CA, USA.
Iain B McInnesInstitute of Infection Immunity and Inflammation, University of Glasgow, Glasgow, UK.
Daniel H SolomonDivision of Rheumatology, Brigham and Women's Hospital, Boston, MA, USA.
Vibeke StrandDivision of Immunology and Rheumatology, Stanford University, Palo Alto, CA, USA.
Kazuhiko YamamotoLaboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Medical University of Vienna · ATUniversity of California, San Diego · USBrigham and Women's Hospital · USChapel Allerton Hospital · GBCharité - Universitätsmedizin Berlin · DENIHR Manchester Biomedical Research Centre · GBRIKEN Center for Integrative Medical Sciences · JPStanford University · USUniversity of Glasgow · GB

Funding

Department of Health RC-PG-0407-10054Medical Research Council MR/K015346/1Versus Arthritis 18475Versus Arthritis 20639
6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a chronic, inflammatory, autoimmune disease that primarily affects the joints and is associated with autoantibodies that target various molecules including modified self-epitopes. The identification of novel autoantibodies has improved diagnostic accuracy, and newly developed classification criteria facilitate the recognition and study of the disease early in its course. New clinical assessment tools are able to better characterize disease activity states, which are correlated with progression of damage and disability, and permit improved follow-up. In addition, better understanding of the pathogenesis of RA through recognition of key cells and cytokines has led to the development of targeted disease-modifying antirheumatic drugs. Altogether, the improved understanding of the pathogenetic processes involved, rational use of established drugs and development of new drugs and reliable assessment tools have drastically altered the lives of individuals with RA over the past 2 decades. Current strategies strive for early referral, early diagnosis and early start of effective therapy aimed at remission or, at the least, low disease activity, with rapid adaptation of treatment if this target is not reached. This treat-to-target approach prevents progression of joint damage and optimizes physical functioning, work and social participation. In this Primer, we discuss the epidemiology, pathophysiology, diagnosis and management of RA.

Indexed as

Antirheumatic AgentsArthritis, RheumatoidDisease ProgressionEarly DiagnosisEpigenomicsGlucocorticoidsHumansMass ScreeningMethotrexateQuality of LifeRisk FactorsAntirheumatic AgentsGlucocorticoidsMethotrexate

Identifiers

PMID29417936
OpenAlexW4211054359

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.